Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1628301

	registered interest
	date	16/05/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Advanced Therapy Medicinal Products
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of reviewing the way the National Institute for Health and Care Excellence and NHS England evaluate and adopt Advanced Therapy Medicinal Products as technologies with the potential to deliver significant health gains over long periods of time.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	185240
	answer	answer is ministerial correction date of answer 25/05/2023 answer text <p>The National Institute of Health and Care Excellence (NICE) recently carried out a comprehensive review of its methods and processes for health technology evaluation to ensure that they were appropriate to emerging new technologies such as advanced therapeutic medicinal products (ATMPs). NICE published its updated health technology evaluation manual in January 2022 and has introduced a number of changes that ensure that its appraisal processes are suitable for emerging new medicines, including a broader severity modifier and changes to better respond to uncertainty. There are no plans for a further assessment of NICE’s processes for evaluating ATMPs.</p><p> </p><p>NICE’s methods and processes have been proven to be suitable for ATMPs where companies are willing to price their products in a way that represents value to the taxpayer. NICE has recommended 80% of the ATMPs it has evaluated for use by the National Health Service and they are now available for the treatment of NHS patients, including through the Cancer Drugs Fund and managed access agreements negotiated between the NHS and the manufacturer.</p> answering member constituency Colchester answering member printed Will Quince question first answered 25/05/2023 12:35:12 answering member 4423 label Biography information for Will Quince
	tabling member	3960 label Biography information for Henry Smith

1628299

	registered interest
	date	16/05/2023
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Food: Labelling
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Environment, Food and Rural Affairs, whether he plans to introduce mandatory animal-welfare labelling on supermarket products.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	185239
	answer	answer is ministerial correction date of answer 23/05/2023 answer text <p>In 2021, Defra ran a call for evidence to gather data on the potential impacts of different types of labelling reform for animal welfare. We received over 1,600 responses and a summary of these responses is available on GOV.UK.</p><p> </p><p>Based on the evidence provided, Defra committed in the Government’s Food Strategy to consult on improving and expanding mandatory animal welfare labelling, covering both domestic and imported products, in 2023.</p> answering member constituency Sherwood answering member printed Mark Spencer question first answered 23/05/2023 11:48:31 answering member 4055 label Biography information for Sir Mark Spencer
	tabling member	3960 label Biography information for Henry Smith

1628302

	registered interest
	date	16/05/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gene Therapies
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential support for UK leadership in the adoption of cell and gene therapies of the recommendations of the Cell and Gene Therapy Catapult’s National Cell and Gene Therapy Vision for the UK, published in March 2022.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	185241
	answer	answer is ministerial correction date of answer 23/05/2023 answer text <p>The Department recognises that advanced cell and gene therapies will be an important part of the future of healthcare and the life sciences industry. We have been considering the recommendations of the Cell and Gene Therapy Catapult’s ‘National Cell and Gene Therapy Vision for the UK’, a report published by the Cell and Gene Therapy Catapult in March 2022 and the UK Strategic Stem Cell Forum’s latest report ‘A 10-year vision for stem cell transplantation and cellular therapies’ published in July 2022.</p><p>As part of this, we have been conducting stakeholder engagement to further understand the challenges raised and whether there is a role for the Department in coordinating activity in this area.</p> answering member constituency Colchester answering member printed Will Quince question first answered 23/05/2023 15:10:28 answering member 4423 label Biography information for Will Quince
	tabling member	3960 label Biography information for Henry Smith